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COMMENTARYA balanced perspective for management of tracheal salivary
gland-type carcinomasChadrick E. Denlinger, MDI read with great interest the article by Wurtz and colleagues
describing their experience with aortic allografts for tracheal
reconstruction after resection of salivary gland–type tumors.
A series of 6 patients underwent tracheal resection for ade-
noid cystic carcinoma (ACC) (n ¼ 5) or a mucoepidermoid
tumor (n ¼ 1). Three patients required tracheal resections
measuring 5.5, 9, and 10.5 cm. Resections in the remaining
3 patients extended from the first, second, or sixth tracheal
ring to at least the level of the carina. Negative resection
margins were achieved by frozen section analysis in each
case. An average of 5.3 frozen sections was required, and
it is unclear how much additional tracheal length was re-
sected to achieve negative margins compared with the initial
resection. In each case, the trachea was reconstructed with an
aortic allograft supported with a silicone stent.
With a mean follow-up of 32 months, several significant
complications were honestly described by the authors. These
complications included tracheoesophageal fistulas (n ¼ 3),
an anastomotic dehiscence, anterior spinal cord ischemia,
sternal dehiscence, acquired respiratory distress syndrome,
and a single patient who required 11 tracheal stent replace-
ments. Two patients required a tracheostomy, and the
mean length of hospital stay was 46 days. At the time of ar-
ticle submission, 4 of 6 patients were free of disease. One pa-
tient had died of distant metastatic disease, and another
patient died of massive hemoptysis.
The authors should be congratulated for their attempts to
advance our ability to surgically treat central airway tumors.
The described case series represents a logical step following
their own previously published report of 2 cases1 and prior
large animal studies.2 However, this operation, with the nu-
merous major complications, should be interpreted in the
context of more traditional treatment strategies.
Microscopically positive margins in patients with ACC
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sal and perineural invasion. Maziak and associates3 reported
actuarial survivals of 79% and 51% at 5 and 10 years, re-
spectively, for patients with ACC. Fifty percent of the 32 pa-
tients had microscopic evidence of disease at the resection
margins, which resulted in a slight decrease in median sur-
vival (7.5 vs 9.8 years). An additional 6 patients in this series
had unresectable disease and were treated with external beam
radiation, resulting in a median survival of 6.2 years. Interest-
ingly, this series reported a 30-day mortality in 3 of 32 pa-
tients treated surgically. Two of the 3 who died during the
30-day operative period required reconstruction with a pros-
thetic mesh. Similarly, a large series of tracheal resections
with primary anastomoses and adjuvant radiation by Grillo
and Mathisen4 included 60 patients with ACC. No survival
difference was noted between patients with positive surgical
margins and patients undergoing complete resection.
Although achieving negative resection margins intui-
tively seems more acceptable than microscopic residual
disease, the frequency of severe complications associated
with tracheal replacement strategies may render the treat-
ment worse than the disease. Further advancements need
to be made before tracheal replacement for salivary gland
tumors becomes the standard treatment.References
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